BioHarvest's Q3 sales fell from $9.1 million to $7.9 million, and its operating loss widened from $0.9 million to $3 million. It held $12.5 million in cash and is moderating lower-return customer acquisition, but the reported results make the story unfavorable.
That choice could make sales more profitable, but the report does not yet show an improvement. Cash on hand and plans to focus on advanced manufacturing programs offer some support. Still, the operating loss grew, and the report gives no results from those programs.
Follow BioHarvest Sciences Inc. (BHST) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for BHST